First, do no harm: The unclear benefit of lifelong castration for patients with metastatic prostate cancer

Sena, Laura A.; Wang, Hao; Denmeade, Samuel R.

doi:10.1002/pros.24582

Cited by 1 publication

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study from the United Kingdom reported that almost 50% of men living with advanced prostate cancer experience poor quality of life and, not surprisingly, the degree of advancement of the prostate cancer diagnosis correlated with diminution in the quality of life [151]. In addition to insomnia and depressive symptoms, hot flushes induced by ADT may also negatively affect quality of life [152][153][154][155]. Although there are no targeted treatments to mitigate the worsening of quality of life that may accompany ADT, a healthy lifestyle with regular physical activity may be of benefit in reducing fatigue and minimizing the increase in fat mass induced by ADT [156].…”

Section: Adt Impact On Quality Of Lifementioning

confidence: 99%

Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood

Reiss,

Gulkarov,

Pinkhasov

et al. 2023

Medicina

View full text Add to dashboard Cite

Prostate cancer is the second leading cause of cancer death in men in the United States. Androgen deprivation therapy (ADT) is currently the primary treatment for metastatic prostate cancer, and some studies have shown that the use of anti-androgen drugs is related to a reduction in cognitive function, mood changes, diminished quality of life, dementia, and possibly Alzheimer’s disease. ADT has potential physiological effects such as a reduction in white matter integrity and a negative impact on hypothalamic functions due to the lowering of testosterone levels or the blockade of downstream androgen receptor signaling by first- and second-generation anti-androgen drugs. A comparative analysis of prostate cancer patients undergoing ADT and Alzheimer patients identified over 30 shared genes, illustrating common ground for the mechanistic underpinning of the symptomatology. The purpose of this review was to investigate the effects of ADT on cognitive function, mood, and quality of life, as well as to analyze the relationship between ADT and Alzheimer’s disease. The evaluation of prostate cancer patient cognitive ability via neurocognitive testing is described. Future studies should further explore the connection among cognitive deficits, mood disturbances, and the physiological changes that occur when hormonal balance is altered.

show abstract